Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEMODE pilot open-label study of nemolizumab in dystrophic epidermolysis bullosa
2026-526417-28-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemolizumab in dystrophic epidermolysis bullosa (DEB), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Change in Peak Pruritus Numerical Rating Scale. Planned start Oct 2026; status: authorised.
02
Drugs
nemolizumab
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on 2026-526417-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526417-28-00.